Date: 2015-06-26
Type of information: Nomination
Compound:
Company: DBV Technologies (France)
Therapeutic area: Allergic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 26, 2015, DBV Technologies announced the appointment of Dr. Hugh Sampson as Chief Scientific Officer (CSO). In this new role and in partnership with Dr. Dupont, chairman of the Company’s Scientific Advisory Board, Dr. Sampson will lead DBV’s research team, pursuing new Viaskin® applications for the treatment of food allergies, while also supporting the Company’s clinical development teams. Dr. Sampson’s appointment as CSO will become effective on November 1, 2015. Dr. Sampson will also continue serving as an advisor to the Company, as well as Director of the Research Center at the Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food Allergy Institute; and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the State University of New York at Buffalo School of Medicine. Dr. Sampson\'s research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of food-induced anaphylaxis, the characterization of foodinduced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies (recombinant engineered protein, plasmid DNA, peptide, etc.) for treating food allergies. His research has been funded by a number of grants from the National Institutes of Health (NIH) and private foundations. He is the Principal Investigator of the NIH sponsored Consortium of Food Allergy Research (CoFAR). He is also former President of the American Academy of Allergy Asthma and Immunology (AAAAI).
Financial terms:
Latest news:
